FDA’s Reservation over Multiple Sclerosis Treatment

MSIn a recent report, the Food and Drug Administration has come out to warn against an experimental treatment for multiple sclerosis. It was in the year 2011 that reports had indicated that one of the patients had lost his life after profuse bleeding in the brain, while one more had suffered from paralysis. The slew of reports had raised doubts on the liberation therapy, which is basically aimed for chronic cerebrospinal venous insufficiency (CCSVI).

During the treatment, balloons or stents are inserted into veins so that they can be broadened and risk of MS can be shoved off. However, looking at the symptoms of the therapy, it appears that things can go wrong too after one goes through the treatment.

Since there is no central registry of such patients, thus it has become all the more complicated to know how many Americans have gone through the treatment. "We're still determining the risks associated with this”, said Tim Coetzee, Chief Researcher for the National Multiple Sclerosis Society, while asserting that there is no clarity about the potential associating between the side effects and MS. Though drugs are available to deal with the symptoms, it has been claimed that there is no cure as of now present for MS victims.

It would be worth seeing if the drug regulator would be able to clear the picture over the drug in the time to come.